» Articles » PMID: 26248668

Determinants in HIV-2 Env and Tetherin Required for Functional Interaction

Overview
Journal Retrovirology
Publisher Biomed Central
Specialty Microbiology
Date 2015 Aug 8
PMID 26248668
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The interferon-inducible factor BST-2/tetherin blocks the release of nascent virions from the surface of infected cells for certain enveloped virus families. The primate lentiviruses have evolved several counteracting mechanisms which, in the case of HIV-2, is a function of its Env protein. We sought to further understand the features of the Env protein and tetherin that are important for this interaction, and to evaluate the selective pressure on HIV-2 to maintain such an activity.

Results: By examining Env mutants with changes in the ectodomain of the protein (virus ROD14) or the cytoplasmic tail (substitution Y707A) that render the proteins unable to counteract tetherin, we determined that an interaction between Env and tetherin is important for this activity. Furthermore, this Env-tetherin interaction required an alanine face in the tetherin ectodomain, although insertion of this domain into an artificial tetherin-like protein was not sufficient to confer sensitivity to the HIV-2 Env. The replication of virus carrying the ROD14 substitutions was significantly slower than the matched wild-type virus, but it acquired second-site mutations during passaging in the cytoplasmic tail of Env which restored the ability of the protein to both bind to and counteract tetherin.

Conclusions: These results shed light on the interaction between HIV-2 and tetherin, suggesting a physical interaction that maps to the ectodomains of both proteins and indicating a strong selection pressure to maintain an anti-tetherin activity in the HIV-2 Env.

Citing Articles

Human BST2 inhibits rabies virus release independently of cysteine-linked dimerization and asparagine-linked glycosylation.

Tanwattana N, Wanasen N, Jantraphakorn Y, Srisutthisamphan K, Chailungkarn T, Boonrungsiman S PLoS One. 2023; 18(11):e0292833.

PMID: 37922253 PMC: 10624315. DOI: 10.1371/journal.pone.0292833.


Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses.

Vzorov A, Samokhvalov E, Chebanenko V, Scheblyakov D, Gintsburg A Mol Biol. 2021; 55(4):538-547.

PMID: 34465926 PMC: 8390073. DOI: 10.1134/S0026893321030158.


Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2.

Heusinger E, Deppe K, Sette P, Krapp C, Kmiec D, Kluge S J Virol. 2018; 92(18).

PMID: 29976668 PMC: 6146695. DOI: 10.1128/JVI.00276-18.


Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.

Dufrasne F, Lombard C, Goubau P, Ruelle J Viruses. 2016; 8(10).

PMID: 27754450 PMC: 5086617. DOI: 10.3390/v8100285.


Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.

Chen C, Shingai M, Welbourn S, Martin M, Borrego P, Taveira N J Virol. 2016; 90(24):11062-11074.

PMID: 27681141 PMC: 5126365. DOI: 10.1128/JVI.01451-16.

References
1.
Adduci A, Schlegel R . The transmembrane domain of the E5 oncoprotein contains functionally discrete helical faces. J Biol Chem. 1999; 274(15):10249-58. DOI: 10.1074/jbc.274.15.10249. View

2.
Lopez L, Yang S, Hauser H, Exline C, Haworth K, Oldenburg J . Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol. 2010; 84(14):7243-55. PMC: 2898217. DOI: 10.1128/JVI.02636-09. View

3.
Sauter D, Schindler M, Specht A, Landford W, Munch J, Kim K . Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe. 2009; 6(5):409-21. PMC: 2779047. DOI: 10.1016/j.chom.2009.10.004. View

4.
Goto T, Kennel S, Abe M, Takishita M, Kosaka M, Solomon A . A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994; 84(6):1922-30. View

5.
Neil S, Zang T, Bieniasz P . Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008; 451(7177):425-30. DOI: 10.1038/nature06553. View